Accession Number:



Fusion Genes Predict Prostate Cancer Recurrence

Descriptive Note:

Technical Report,15 Sep 2016,14 Sep 2017

Corporate Author:

University of Wisconsin Madison Madison United States

Personal Author(s):

Report Date:


Pagination or Media Count:



This Impact Award between the University of Pittsburgh, Stanford University and University of Wisconsin at Madison seeks to provide definitive clinical validation of low copy number transcript fusions as prognostic markers in clinically localized prostate cancer. The Stanford site is charged with providing formalin fixed paraffin embedded samples for independent validation of markers discovered at University of Pittsburgh. To that end, we have shipped 300 samples for assay testing and have accumulated over 600 FFPE blocks of radical prostatectomy specimens with detailed clinical follow-up. The assay results suggest that there are some artifacts, and University of Pittsburgh will be addressing these issues. Next year we will increase the number of samples accumulated to get to our goals. We will be sending specimens blinded to the Pittsburgh site and include controls for assay performance. We have agreed to allow the Stanford and Wisconsin sites to receive data from Pittsburgh to perform correlation with clinical data and correlation with outcomes at these sites.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: